Verve Therapeutics’ stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment

Analysts raise concerns about comparative effectiveness of experimental cholesterol treatment.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.